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Abstract: High levels of storage iron may increase malaria susceptibility. This risk has not been 
investigated in semi-immune adolescents. We investigated whether baseline iron status of non-
pregnant adolescent girls living in a high malaria transmission area in Burkina Faso affected malaria 
risk during the following rainy season. For this prospective study, we analysed data from an interim 
safety survey, conducted six months into a randomised iron supplementation trial. We used logistic 
regression to model the risk of P. falciparum infection prevalence by microscopy, the pre-specified 
interim safety outcome, in relation to iron status, nutritional indicators and menarche assessed at 
recruitment. The interim survey was attended by 1223 (82%) of 1486 eligible participants, 1084 (89%) 
of whom were <20 years at baseline and 242 (22%) were pre-menarcheal. At baseline, prevalence of 
low body iron stores was 10%. At follow-up, 38% of adolescents had predominantly asymptomatic 
malaria parasitaemias, with no difference by menarcheal status. Higher body iron stores at baseline 
predicted an increased malaria risk in the following rainy season (OR 1.18 (95% CI 1.05, 1.34, p = 
0.007) after adjusting for bed net use, age, menarche, and body mass index. We conclude that routine 
iron supplementation should not be recommended without prior effective malaria control. 
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1. Introduction 
Iron deficiency (ID) is a lack of mobilisable iron stores with a compromised supply of iron to 
tissues [1]. Iron deficiency anaemia (IDA) represents a population sub-group with iron-deficient 
erythropoiesis. It is estimated that one third of women of child-bearing age will be anaemic, of whom 
one half will be iron deficient as a result of menses and poor diets [2]. A Sustainable Development 
Goal for 2025 is a 50% reduction of anaemia in women of reproductive age including non-pregnant 
(NP) menstruating adolescents [3]. Current guidelines, where anaemia prevalence is >20%, 
recommend intermittent oral weekly iron and folic acid (IFA) (60 mg iron and 2.8 mg FA) for a period 
of three months, withdrawal for three months, then recommencement [4]. With anaemia prevalence, 
>40% daily iron (30–60 mg) is advised for three consecutive months each year. Intermittent 
supplementation (weekly—once, twice, or more doses) is recommended by the World Health 
Organization (WHO) in order to reduce side effects and non-adherence associated with daily 
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regimes, although daily iron continues to be recommended during pregnancy [5]. There is evidence, 
mostly from studies outside of sub-Saharan Africa, of improvements of NP adolescent haemoglobin 
levels following iron supplementation [6], but in Burkina Faso, our randomised controlled trial 
showed a lack of efficacy of weekly iron supplementation in both NP and pregnant cohorts [7].  
IDA contributes to anaemia prevalence, but in much of sub-Saharan Africa, malaria is the more 
important cause [8]. A meta-analysis, based on national surveys and using adjusted ferritin levels to 
measure iron, reported a lower than expected ID prevalence (17.8%; 95% CI: 13.4, 22.3) among women 
of reproductive age in countries with a high burden of infection-drive inflammation [9]. Malaria 
affects iron metabolism, so malaria-induced destruction of red blood cells hinders reticuloendothelial 
macrophages in recycling iron back to the bone marrow, leading to anaemia [10]. The relative 
contribution of ID to the overall burden of anaemia raises critical risk assessment issues in malaria 
endemic areas, given long-standing concerns that better iron status could increase susceptibility to 
malaria [10,11] and possibly enteric infections [12,13]. In a prospective Zambian study, children under 
six years of age with higher iron stores had an elevated malaria risk during the high malaria season 
[14]. Similarly, in primigravidae, we reported a higher risk of early gestational malaria with increased 
body iron stores (relative risk 1.53, 95% CI 0.67–2.38, p < 0.001) [15]. Cochrane reviews in children [16] 
and non-adolescent parous menstruating women of child bearing age [4], however, support, and 
consider it safe to provide IFA supplements in malaria endemic areas provided malaria surveillance 
and control strategies are in place [17]. The IFA recommendations for menstruating adolescents are 
nonetheless based on very limited evidence [18–21]. 
Improving the nutritional status of adolescents is justifiably one of the key actions highlighted 
by the Global Accelerated Action for the Health of Adolescents programme [22]. Weekly adolescent 
IFA programmes have already been introduced in more than ten Asian/African countries [23] and 
may improve adolescent health in non-malaria endemic regions. The aim of this paper was to 
examine the effect of adolescent iron status on malaria risk in a high transmission setting in Burkina 
Faso, one of 21 countries accounting for 85% of global malaria deaths in 2018 [24]. Using iron 
biomarkers and nutritional data collected at recruitment to a community-based randomised 
controlled trial of iron supplements [7], we prospectively assessed NP adolescent malaria risk at the 
pre-specified interim safety survey conducted in the following rainy/malaria season, approximately 
six months after recruitment. We found that better iron status at the baseline increased subsequent 
malaria risk. 
2. Materials and Methods 
2.1. Ethics Statement 
This survey was conducted as part of a randomised, double blind controlled non-inferiority trial 
conducted in rural Burkina Faso between April 2011 and January 2014. The study received ethical 
approvals in Burkina Faso; National Ethics Committee (CERS Ref 015-2020/CE-CM) and the Comité 
d’Ethique pour la Recherche en Santé du Centre Muraz; the United Kingdom Research Ethics 
Committee, Liverpool School of Tropical Medicine (LSTM/REC protocol 10–55); the Institutional 
Review Board of the Institute of Tropical Medicine (IRB/AB/AC/016), and the Antwerp University 
Hospital Ethics Committee, Belgium (EC/UZA). The trial was registered with Clinicaltrials.gov on 27 
September 2010: trial registration number NCT01210040. Written, informed consents were given by 
all individuals, with additional guardian consents provided for minors. The work described was 
carried out in accordance with the Code of Ethics of the World Medical Association. (Declaration of 
Helsinki). The main results of the study were communicated to the communities at the end of the 
study. 
2.2. Background to the Trial 
Recruitment started in April 2011 in thirty rural villages in the Nanoro Health and Demographic 
Surveillance System catchment area, situated 85 km from Ouagadougou where malaria is hyper-
endemic [25]. The entomological inoculation rate in this area is estimated to be 50–60 infective 
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bites/person/year (Diabaté A., personal communication). Plasmodium falciparum accounts for nearly 
all severe malaria cases and almost half of all outpatient consultations. National government malaria 
control activities are based on diagnosis and treatment of suspected cases, free long lasting 
insecticidal bed net (LLIN) distribution, and intermittent preventive treatment for pregnant women. 
Healthy nulliparous, NP women aged 15–24 years, less than 40% of whom were literate [13], 
were recruited to receive either weekly ferrous gluconate (60 mg) with folic acid (2.8 mg) as 
intervention or folic acid alone as the control, following the WHO guidelines updated in 2016 [26]. 
Participants were visited at home each week by field workers who directly observed ingestion of 
capsules and monitored for pregnancy and symptoms of illness. In cases of fever (temperature ≥ 37.5 
°C) or history of fever in the previous 48 h, the field worker performed a malaria Rapid Diagnostic 
Test (RDT) and if positive, collected a blood sample for a thick film. RDT positives were referred to 
the Health Centre and treated at no cost with artesunate-amodiaquine, following national guidelines. 
The RDT targeted HRP2 antigen (Bioline SD, Malaria Antigen Pf 05FK50) had a demonstrated high 
detection rate (97.5%) for low parasite density infections and a zero false positive rate on the WHO 
Product testing round [27]. Bed net use was self-reported as having slept under a net the previous 
night. Supplement adherence for each woman was computed as the number of weekly treatments 
received divided by the number of weeks on the trial. 
2.3. Baseline Assessment 
At enrolment, demographic data and medical histories were recorded including history of 
illness, last menstrual period, and age at menarche, together with clinical examination. Height 
(nearest mm), weight (nearest 100 g), and mid-upper arm circumference (mm: MUAC) were 
measured in duplicate. A 5 mL venous blood sample was collected for later iron biomarker 
assessments. Body Mass Index (BMI) was computed and transformed into an age-specific Z-score 
based on the 2007 WHO normative standards [28]. Haemoglobin was not measured at the baseline. 
Women were not recruited if they had clinical signs of severe anaemia (conjunctival or mucosal 
pallor, tachycardia, respiratory distress), or a history or presence of major clinical disease. HIV 
prevalence was low (<2%) in the general population. Malaria parasitaemia was not assessed. 
Symptomatic women were referred to the nearest health centre. All participants received aLLIN) and 
single doses of albendazole (400 mg) and praziquantel.  
2.4. Interim Safety Survey 
Following recruitment in the dry season, the interim survey took place in the first malaria season 
(November/December 2011) after approximately six months supplementation. The purpose was to 
conduct a blinded interim analysis of safety, based on malaria prevalence in the two trial arms, with 
pre-specified stopping rules for malaria prevalence and a review of other safety data. All NP 
participants recruited prior to that date were included (a further cohort of women were recruited to 
the trial after this date, thus, the numbers here were smaller than those reported elsewhere on the 
main trial). In addition to the data collected routinely at the weekly visit, a finger prick blood sample 
for a RDT test and malaria blood smear for microscopy were collected and the previous night’s bed 
net use was ascertained. Positive RDTs were treated following the national guidelines. Non-attendees 
were screened at a successive weekly visit during the period of the interim survey, if available. 
Following an independent review of this data, the Data Monitoring Committee recommended 
that the trial should continue as planned and recruitment and follow-up should continue.  
2.5. Laboratory Tests 
2.5.1. Assessment of Iron Status 
At the baseline survey, blood was transported to the research laboratory and within three hours, 
centrifuged, aliquoted, and stored at −80 °C. Ferritin and serum transferrin receptor (sTfR) were 
measured using duplicate sampling by Enzyme-linked Immunosorbent Assay (ELISA) (Spectro 
Ferritin S-22 and TFC 94 Transferrin Receptor, RAMCO Laboratories Inc, Texas) at the Research 
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Laboratory in Nanoro, and C-reactive protein (CRP) by ELISA (EU59131IBL International, GmbH, 
Hamburg). Intra-assay coefficients of variation were all <10%. Serum hepcidin was measured in the 
Netherlands by competitive ELISA assay as previously described [29]. Body iron stores (BIS) (mg/kg) 
were calculated using the equation derived by Cook et al.: body iron (mg/kg) = −[log10 (1000 × 
sTfR/ferritin) − 2.8229]/0.1207 [30].  
Iron deficiency and iron status were estimated using specific biomarker definitions with 
adjusted ferritin estimates allowing for inflammation. These were: 
1. Unadjusted ferritin <15 μg/L [1] and adjusted ferritin were used. Adjusted ferritin was based on 
the internal regression correction approach described by Namaste et al. [31], allowing for 
inflammation as described by Mei et al. [32]. 
2. A non-pregnant internal regression slope log (ferritin) against log (CRP) estimate was used for 
ferritin correction, adjusting ferritin levels where CRP exceeded a reference level of the tenth 
centile to that reference level [15]. 
3. sTfR concentration of >8.3 μg/mL [33]. 
4. Ratio of sTfR (mg/L) to log10 adjusted ferritin (μg/L) >5.6, which assesses both stored and 
functional iron and is possibly less affected by inflammation. The ratio derives from the cut-offs 
sTfR > 8.3 μg/mL and ferritin < 30 μg/L. RAMCO was the assay used for sTfR, as its cut-off (>5.6) 
best predicted iron deficient bone marrow stores (sensitivity 74%, specificity 73%, accuracy 73%), 
in another area of high malaria transmission [34]. 
5. The median hepcidin reference level of serum/plasma based on a healthy non-malarious Dutch 
population [35]. The hepcidin 95% reference range for women 18–24 years of age from that 
population was: median 2.6 nM; 2.5th percentile 0.7 nm; and 97.5th percentile 10.5 nM.  
6. BIS was calculated using the regression-adjusted ferritin estimate. Low body iron was defined 
as zero iron stores <0 mg/kg. 
2.5.2. Assessment of Malaria 
Whole blood for malaria films were Giemsa stained and read by two qualified microscopists. 
For discrepant findings (positive/negative; >two-fold difference for parasite densities ≥400 μL; >log10 
if < 400 μL), a third independent reading was made. Parasite density was calculated by counting the 
number of asexual parasites per 200 white blood cells in the thick blood film by light microscopy at 
100× magnification. The parasite density per μL was calculated assuming a white cell count of 8000 
mm. Clinical malaria was defined as a positive blood slide with fever (≥37.5 °C) or history of fever. 
2.6. Statistical Analysis 
There was no difference in malaria prevalence risk by trial arm at the interim survey (Table 1, 
Fisher’s Exact Test: p = 0.77). For the remaining interim assessments, data from both trial arms were 
therefore combined. 
Table 1. Parasite prevalence by treatment arm at interim survey. 
Iron Controls 
n/N % (95% CI) n/N % (95% CI) 
222/611 36 (32.0–39.9) 226/612 36.9 (33.2–40.8) 
Associations of anthropomorphic measures and iron biomarkers with age and menarcheal status 
were assessed using linear regression models, fitting a common slope for menarcheal and non-
menarcheal girls. An interaction term (different slopes) was considered, but not presented as there 
was no statistical evidence for different slopes, nor was there evidence of non-linear effects. 
Significance values are presented for the age (slope) and menarche effects. Skewed biomarker values 
were log-transformed. Mean values and 95% confidence intervals (CI) for each integer age are 
presented. The relationships between malaria prevalence and age and BMI (Z-score) were similarly 
analysed using analogous logistic regression models. 
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Similar logistic regression models were used to quantify the relationships between malaria 
prevalence at the interim survey and baseline iron biomarkers. A linear, iron effect was fitted for the 
menarcheal and non-menarcheal groups as there was no statistical evidence for an interaction effect 
or for any non-linear behaviour. Fitted lines are presented with rug plots to indicate actual data 
values. Multivariable logistic regression was used to assess the relationship between iron biomarkers 
and malaria prevalence, after adjusting for age and BMI (expressed as Z-score) as linear terms, and 
bed net use and menarcheal status at the time of assessment as categorical variables. More complex 
models were considered, but did not improve the fit to the data. Each biomarker was then tested in 
turn as an addition to this 4-variable base model. Biomarkers were standardised by the mean and 
standard deviation of the observed distribution in the sample in order to obtain comparable odds-
ratio estimates between biomarkers. All analyses were conducted in the R statistical environment 
(v3.6). 
3. Results 
3.1. Sample Description 
A total of 1486 NP females were eligible for the interim safety survey, which was completed by 
1223 (82%). The number re-screened included 1084 adolescents (<20 years) and 139 young adults (20–
24 years) (Table 2).  
Table 2. Clinical parameters at the baseline and interim wet season assessment in all women and 







Median age, years (IQR)(N) 16 (16–18) (1223) 16 (16–18) (1084) 
Menarcheal, n/N (%) 978/1223 (80) 842/1084 (78) 
Median reproductive age, years (IQR)(N) 2 (1–3) (978) 1 (1–2) (842) 
Became pregnant during trial, n/N(%) 291/1223 (24) 251/1084 (23) 
Median BMI, kg/m2 (IQR)(N) 19 (18–21) (1223) 19 (18–21) (1084) 
Median BMI Z score (IQR)(N) −0.6 (−1.1–−0.1) (1223) −0.6 (−1.1–−0.1) (1084) 
Median MUAC, cm (IQR)(N) 24 (22–25) (1223) 23 (22–25) (1084) 
Bed net use a n/N(%) 392/1223 (32) 336/1084 (31) 
At Interim Assessment 
Median age, years (IQR)(N) 17 (16–19) (1223) 17 (16–18) (1084) 
Menarcheal, n/N (%) 1073/1223 (88) 934/1084 (86) 
Median Reproductive age, years (IQR)(N) 2 (1–3) (1073) 1 (1–2) (934) 
Bed net use a n/N (%) 914/1198 (76) 813/1061 (77) 
Median weeks on supplementation (IQR)(N) 22 (17–26) (1223) 22 (18–26) (1084) 
Median % adherence b (IQR)(N) 69 (56–79) (1223) 69 (56–79) (1084) 
Iron Biomarkers at Baseline 
Median CRP mg/L (IQR)(N) 0.653 (0.262–1.571) (1216) 0.663 (0.261–1.588) (1078) 
Median GM adjusted ferritin, μg/L, (IQR)(N) c 40.4 (22.5–64.2) (1214) 41.2 (24.0–65.3) (1075) 
Adjusted ferritin < 15 μg/L, n/N (%) c 178/1214 (15) 137/1075 (13) 
Median GM sTfR μg/mL, (IQR)(N) 6.46 (5.34–8.01) (1216) 6.44 (5.34–7.94) (1078) 
sTfR > 8.3 μg/mL, n/N (%) 276/1216 (23) 236/1078 (22) 
Median sTfR/log10 ferritin c, (IQR)(N) 4.07 (3.17–5.75) (1213) 4.02 (3.17–5.50) (1075) 
sTfR/log10 ferritin c > 5.6, n/N (%) 320/1213 (26) 265/1075 (25) 
Median hepcidin nmol/L (IQR)(N) 4.8 (2.0–10.4) (1213) 5.0 (2.2–10.7) (1076) 
Hepcidin < 0.7 nmol/L, n/N (%) d 112/1213 (9)  84/1076 (8)  
Median adjusted BIS c, mg/kg (IQR)(N) 5.2 (2.7–7.1) (1213) 5.3 (2.8–7.1) (1075) 
Low adjusted BIS < 0 mg/kg, n/N (%)  118/1213 (10)  88/1075 (8) 
IGR: Interquartile range; BMI: Body mass index; MUAC: Mid-upper arm circumference; GM: 
geometric mean; BIS: body iron stores; sTfR: serum transferrin receptor; CRP: C-reactive protein; a 
Women reporting sleeping under a bed net the night previous to assessment; b Percentage of directly 
observed weekly supplements; c Ferritin and BIS adjusted for inflammation using an internal 
regression correction (see Methods); d The 2.5th percentile of the reference range for healthy Dutch 
women aged 18–24 years. 
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The reasons for non-attendance are shown in the participant flow diagram (Figure 1). 
 
Figure 1. Participant flow. 
Of the adolescents, 22% (242) were non-menarcheal at baseline (Table 2). Mean BMI and MUAC 
rose with age in both groups, but non-menarcheal had lower values than menarcheal girls (Figure 2). 
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Figure 2. Age specific body mass index (BMI) and mid-upper arm circumference (MUAC) in 
menarcheal and non-menarcheal participants measured at the baseline. Error bars represent the mean 
and 95% CI for each age group and are slightly offset for clarity. Red: menarcheal; Blue: non-
menarcheal. Lines are a quadratic fit to aid visualisation. Stippled vertical line indicates the adolescent 
cohort (<20 years). 
3.2. Iron Biomarker Profiles at the Baseline Survey 
Iron deficiency prevalence ranged from 10% with low adjusted BIS (<0 mg/kg) to 26% using the 
sTfR/log10 ferritin >5.6. (Table 2) In Figure 3, values for four iron biomarkers are plotted by age and 
menarcheal status. Regression slopes for this figure are included in Supplementary File 1 as 
Supplementary Table S1. Adjusted ferritin (p < 0.001), hepcidin (p < 0.001), and adjusted BIS (p < 0.001) 
decreased and the sTfR/log10 ferritin ratio (p = 0.004) increased with age. The same trends were seen 
in non-menarcheal girls with very little difference between menarcheal and non-menarcheal girls 
after adjusting for age. 
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Figure 3. Baseline iron biomarkers by age for menarcheal and non-menarcheal participants. Error bars 
represent the mean and 95% CI for each age group and are slightly offset for clarity. Red: menarcheal; 
Blue: non-menarcheal. Lines are linear regression fits assuming a common slope for menarcheal and 
non-menarcheal girls. Significance levels are shown for the slope (Page) and the difference between 
menarcheal and non-menarcheal (Pmen). Stippled vertical line indicates the adolescent cohort (<20 
years). Regression slopes are included in Supplementary File 1 as Supplementary Table S1. 
3.3. Malaria Indices at the Interim Safety Survey 
Field workers visited participants for a minimum of 12 weeks (median 22, IQR 17–26 weeks). On 
the night previous to the survey, 76% reported sleeping under a bed net. Malaria blood slides were 
positive for 38% of adolescents; 53% were RDT positive, with similar proportions for all women 
(Table 3). Only 4% had clinical malaria. Median parasite density in adolescents was 231 
parasites/mm3 (IQR 110–656). For all women both RDT (p = 0.004) and parasite prevalence p < 0.001) 
decreased with age (Figure 4). Regression slopes for this figure are included in Supplementary File 1 
as Supplementary Table S2. Age-specific RDT positivity or parasite prevalence did not differ between 
non-menarcheal and menarcheal women. Neither parasite prevalence (p = 0.21) nor RDT positivity (p 
= 0.35) decreased significantly with increasing BMI when age-adjusted using Z-scores.  
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Table 3. Malaria indices at the interim wet season survey in all women and adolescents of the study 
population. 




Microscopy positive, n/N (%) a 446/1223 (36) 414/1084 (38) 
Fever, n/N (%) b 132/1202 (11) 117/1065 (11) 
Clinical malaria, n/N (%) c 53/1218 (4) 47/1079 (4) 
RDT positive, n/N (%) d 605/1177 (51) 551/1044 (53) 
Parasite density, parasites/mm3, median (IQR)[N] 227 (105–614) (446) 231 (110–656) (414) 
a P. falciparum blood smear positive; b Temperature ≥ 37.5 °C; c P. falciparum blood smear positive and 
fever ≥ 37.5 °C; d RDT: Rapid diagnostic malaria test. 
 
Figure 4. Malaria prevalence by age and BMI Z-score at wet season survey. Error bars represent the 
exact binomial 95% CI for each age or BMI group and are slightly offset for clarity. Red: menarcheal; 
Blue: non-menarcheal. Lines are logistic regression fits assuming a common slope for menarcheal and 
non-menarcheal girls. Significance levels are shown for the slope (Page) and the difference between 
menarcheal and non-menarcheal (Pmen). Stippled vertical line indicates the adolescent cohort (<20 
years). Regression slopes are included in Supplementary File 1 as Supplementary Table S2. 
3.4. Baseline Iron Status and Malaria Prevalence at the Interim Survey 
A regression analysis, (regression slopes in Supplementary File 1 as Supplementary Table S3) 
that included all women, examined the presence of malaria parasitaemia at the interim survey against 
four baseline iron biomarkers (Figure 5). Parasitaemia prevalence increased with indicators of better 
iron status, that is, higher adjusted ferritin (p = 0.007), BIS (p = 0.002) or hepcidin (p = 0.049, whereas 
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it decreased with higher sTfR/log10 ferritin ratios (p = 0.003), indicating poorer iron status. A similar 
pattern of associations was observed for non-menarcheal girls (Figure 5). 
 
Figure 5. Logistic regression fits for parasite prevalence (microscopy positive) against iron 
biomarkers. Red: menarcheal; Blue: non-menarcheal. Fitted regression lines based on a cubic-spline 
fit with a common shape for the two groups. Rugs along the bottom and top axes indicate negative 
and positive girls, respectively. Significance levels are shown for the slope (PFe) and the difference 
between menarcheal and non-menarcheal (Pmen). Regression slopes are included in Supplementary 
File 1 as Supplementary Table S3. 
A multivariable analysis was conducted that adjusted for bed net use, age, menarche, and BMI, 
testing for independent associations with malaria (Table 4). Malaria prevalence assessed by 
microscopy or RDT decreased independently with increasing age. Increasing baseline BIS was 
associated with higher risk of malaria (OR 1.18, 95% CI 1.05, 1.34, p = 0.007), whereas increasing 
baseline sTfR/log10 ferritin ratios were associated with lower risk (0.84, 95%CI 0.74, 0.96, p = 0.007). 
Bed net use the night previous was associated with RDT positivity, but not microscopy positivity. 
Menarche and BMI were not independently associated with malaria.  
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Table 4. Baseline parameters and adjusted risk estimates for malaria at the interim survey. 
Parameter 





Bed nets a 1.50 (1.14–1.97) 0.003 1.01 (0.77–1.34) 0.930 
Age 0.91 (0.85–0.97) 0.007 0.88 (0.82–0.95) 0.002 
Menarche 1.44 (0.97–2.13) 0.069 0.80 (0.54–1.18) 0.260 
BMI Z score 0.88 (0.75–1.04) 0.130 0.98 (0.83–1.16) 0.850 
Log10 (Adjusted Ferritin) 1.15 (1.02–1.30) 0.021 1.16 (1.03–1.32) 0.016 
sTfR 0.87 (0.77–0.98) 0.024 0.87 (0.76–0.99) 0.035 
Log10 (sTfR/Log10 ferritin ratio) 0.85 (0.75–0.96) 0.007 0.84 (0.74–0.96) 0.007 
Adjusted body iron stores b 1.16 (1.03–1.31) 0.014 1.18 (1.05–1.34) 0.007 
Log10 (Hepcidin) 1.13 (1.00–1.27) 0.043 1.10 (0.97–1.24) 0.140 
a Slept under bed net on previous night; b Ferritin and body iron stores adjusted for inflammation 
using an internal regression correction (see Methods). Logistic regression model adjusting for bed net 
use, age, menarche, and BMI; Iron biomarkers are standardised by the sample mean and SD and odds 
ratios expressed per unit on the standardised scale. sTfR: serum transferrin receptor; BMI: Body Mass 
Index. 
4. Discussion 
The interim safety study was conducted in the rainy season to ensure consistently high exposure 
to malaria. At baseline, during the dry season, between 74–90% of rural, largely illiterate, adolescents 
had adequate iron stores. In the rainy season survey, more than half had evidence of malaria 
infections. At a population level, iron deficiency predicted a lower malaria risk six months later, a 
problematic concept when weighing the risks and benefits of an iron intervention [36].  
This was the first study to assess the predictive level of iron stores for subsequent malaria risk 
in a large population of adolescent girls living under hyper-endemic malaria conditions. IFA 
guidelines for menstruating adolescents were largely based on limited evidence from five (GRADE 
low) studies (one providing unpublished data) from malaria endemic regions in sub-Saharan Africa 
[18–21]. Two were early studies [18,19], some did not discriminate pre- and post-pubertal girls [20], 
some sample sizes were small (<280) [18,19,21], all but one [18] were school-based and only two 
reported malaria indices [18,21]. The rationale for routinely providing iron supplements to 
menstruating adolescents (i.e., adolescents of reproductive age) is mainly based on the assumption 
that menses increases the risk of iron deficiency anaemia and that there is a need to conserve iron 
stores before the first pregnancy. Our data showed no difference in iron biomarkers between 
menstruating and non-menstruating girls after controlling for age (Figure 3). We have also shown 
that better iron stores actually increased the risk of malaria early in pregnancy [15]. 
Currently, routine adolescent IFA programmes are considered safe if delivered alongside 
malaria surveillance and control strategies [17]. In our study, despite receiving impregnated bed nets 
at enrolment, with weekly active case detection based on febrile episodes and RDT testing, this level 
of surveillance failed to redress the high prevalence of chronic asymptomatic parasitaemias typical 
of adolescent malaria. Weekly field worker visits only detected symptomatic cases, and clinical cases 
were infrequent, as noted elsewhere for adolescents living in stable malaria transmission areas [37]. 
The reported use of bed nets apparently improved from the baseline, but self-reported net use on the 
previous night has limited reliability [38]. The effectiveness of both adolescent malaria control and 
routine iron supplementation in malaria endemic areas are open to question. We reported no 
reduction in iron deficiency by trial arm in the NP cohort with weekly iron supplementation [7]. Since 
chronic asymptomatic parasitaemias can limit gut iron absorption [39], reductions in IDA with iron 
interventions might be minimal without effective malaria control. In Malawian school children, 
symptomatic management alone made little impact on malaria or anaemia prevalence [40]. In Malian 
school children aged nine to twelve years, when malaria was reduced through a comprehensive 
malaria control strategy including provision of LLIN, malaria education, and intermittent preventive 
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treatment, there were significant improvements in haemoglobin [41]. Since many older girls do not 
attend secondary school, such interventions may be insufficient to reduce re-infections in high 
transmission areas. 
The major strengths of this analysis are the size of the population who attended the interim 
survey, and the fact that malaria exposure was consistently high, being assessed during a short period 
in the rainy season. In total, 18% of participants did not attend the interim survey, largely due to 
temporary absence, as it was not uncommon for young unmarried girls to be sent away to assist other 
households domestically [42], and then re-join the study on their return. For a prevalence survey, the 
large sample size was adequate for accurate estimates of malaria and iron indices, although use of 
rapid tests and microscopy may have underestimated low density (sub-microscopic) parasitaemias. 
Iron status was assessed comprehensively and controlled for inflammation measured by CRP. Data 
on anaemia and malaria at baseline were not collected as this was a trial design requirement. At the 
conclusion of the trial, an end assessment survey for NP women showed that anaemia prevalence 
(Hb < 12 g/dL) was 48.9% in parasitaemic and 39% in non-parasitaemic women, with a prevalence of 
ID below 20% [15].  
Age was an independent predictor of increasing malaria immunity (Table 4), nevertheless many 
older girls experienced asymptomatic infections and hence were untreated. Iron repletion may favour 
malaria transmission as these chronically asymptomatic adolescents represent an important reservoir 
of malaria transmission. In Mali, a country prioritised for high impact malaria control [24], a high 
proportion of P .falciparum infections were concurrently gametocytaemic (51–89%) with a higher 
prevalence in individuals ≤17 years [43]. In Burkina Faso, gametocyte density relative to total parasite 
concentration increases with age, also favouring transmission [44]. An area of research that warrants 
attention is whether body iron status influences gametocyte density. This would require quantifying 
the reproductive rate of infection relative to the population prevalence of iron deficiency and 
repletion. The mechanism explaining the predictive utility of the host iron status at the baseline for 
future malaria risk in the interim survey may relate to both host pathophysiology as well as parasite 
ontogeny in the mosquito [45]. 
5. Conclusions 
National surveys to measure ID and IDA prevalence are required for program planners to 
estimate the impact and cost-effectiveness of improving iron status [9,46], with specific cut-offs for 
justifying IFA supplementation. In high malaria transmission areas, the primary goal should be 
malaria control. Our data also suggest that while iron deficiency cannot be ignored, routine IFA 
should be delayed until adequate malaria control is ensured. So far, such a strategy has been 
unacceptable to public health communities [47]. The challenge is to reduce asymptomatic 
parasitaemias and frequent reinfections and significantly impact this reservoir of malaria 
transmission before introducing IFA programmes. Malaria control should directly result in reduced 
anaemia and improved gut absorption of iron, thereby promoting the effectiveness of IFA. 
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